scispace - formally typeset
J

Joan A. Keiser

Researcher at Parke-Davis

Publications -  49
Citations -  2279

Joan A. Keiser is an academic researcher from Parke-Davis. The author has contributed to research in topics: Receptor & Platelet-derived growth factor receptor. The author has an hindex of 22, co-authored 49 publications receiving 2224 citations. Previous affiliations of Joan A. Keiser include Pfizer & GlaxoSmithKline.

Papers
More filters
Journal ArticleDOI

Vascular Endothelial Growth Factor Upregulates the Expression of Matrix Metalloproteinases in Vascular Smooth Muscle Cells: Role of flt-1

TL;DR: These data are the first to show a direct effect of VEGF on SMCs, and suggest SMC-derived MMPs may be an additional source of proteases to digest vascular basement membrane, which is a crucial step in the initial stage of angiogenesis.
Journal ArticleDOI

Structure−Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors

TL;DR: Screening of a compound library for inhibitors of the fibroblast growth factor and platelet-derived growth factor receptor tyrosine kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosinesine kinase inhibitors, resulting in new analogs with improved potency, solubility, and bioavailability relative to the initial lead.
Journal ArticleDOI

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.

TL;DR: The results indicate that the pressor and adrenal effects observed with torcetrapib and related molecules are independent of CETP inhibition.
Journal ArticleDOI

Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models.

TL;DR: If it is determined that direct intramyocardial injection of angiogenic factors enhances collateral function in patients, this less invasive catheter-based system offers a similar gene delivery efficiency and, thus, may have clear advantages compared with the surgically-based transepicardial injection approach.
Journal ArticleDOI

Thiophene systems. 9. Thienopyrimidinedione derivatives as potential antihypertensive agents.

TL;DR: Results clearly show that all three thiophene systems have potent activity as antihypertensive agents and that 3 and 4 are more potent than 1 or 2 as alpha 1-antagonists in vivo.